Menu
Search
|

Menu

Close
X

Karyopharm Therapeutics Inc KPTI.OQ (NASDAQ Stock Exchange Global Select Market)

7.91 USD
-0.49 (-5.83%)
As of 4:00 PM EDT
Previous Close 8.40
Open 8.36
Volume 508,404
3m Avg Volume 483,655
Today’s High 8.36
Today’s Low 7.89
52 Week High 21.69
52 Week Low 3.93
Shares Outstanding (mil) 47.14
Market Capitalization (mil) 551.05
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.56 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
30
FY17
2
FY16
0
EPS (USD)
FY19
-1.087
FY18
-3.126
FY17
-2.807
FY16
-2.934
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
3,319.60
7.92
Price to Book (MRQ)
vs sector
3.30
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
0.00
14.57
LT Debt to Equity (MRQ)
vs sector
0.00
10.21
Return on Investment (TTM)
vs sector
-69.01
14.49
Return on Equity (TTM)
vs sector
-69.73
15.79

EXECUTIVE LEADERSHIP

Sharon Shacham
President, Chief Scientific Officer, Since 2017
Salary: $450,000.00
Bonus: $183,063.00
Michael Kauffman
Co-Founder, Chief Executive Officer and Director, Since
Salary: $550,000.00
Bonus: $268,625.00
Michael Mason
Chief Financial Officer, Senior Vice President, Treasurer, Since 2019
Salary: --
Bonus: --
Christopher Primiano
Executive Vice President, Chief Business Officer, General Counsel and Secretary, Since 2017
Salary: $404,000.00
Bonus: $204,020.00
Perry Monaco
Senior Vice President of Sales, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

85 Wells Ave
NEWTON CENTER   MA   02459-3298

Phone: +1617.6580600

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

SPONSORED STORIES